Effect of pre-stroke metformin use on early neurological improvement and outcome after intravenous thrombolysis in acute ischemic stroke patients with type 2 diabetes
10.3760/cma.j.issn.1673-4165.2025.05.003
- VernacularTitle:发病前使用二甲双胍对伴2型糖尿病的急性缺血性卒中患者静脉溶栓后早期神经功能改善和转归的影响
- Author:
Rui WANG
1
;
Fengli ZHAO
;
Qiang XUE
Author Information
1. 山西医科大学附属运城市中心医院神经内科，运城 044000
- Keywords:
Ischemic stroke;
Thrombolytic therapy;
Diabetes mellitus, type 2;
Metformin;
Treatment outcome;
Time factor
- From:
International Journal of Cerebrovascular Diseases
2025;33(5):336-342
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of pre-stroke metformin (MET) use on early neurological improvement (ENI) and outcome after intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients with type 2 diabetes (T2DM).Methods:AIS patients with T2DM underwent IVT in the Department of Neurology, Yuncheng Central Hospital from January 2019 to February 2025 were included retrospectively. According to whether MET was used before onset, they were divided into MET group and non-MET group. Early neurological improvement (ENI) was defined as a decrease in the National Institutes of Health Stroke Scale (NIHSS) score ≥4 at 24 hours after IVT compared to admission, or the NIHSS score was 0-1. At 90 days after onset, the modified Rankin Scale was used for outcome assessment, and ≤2 was good outcome and >2 was poor outcome. Multivariate logistic regression analysis was used to determine the independent influencing factors of ENI and outcome. Results:A total of 115 AIS patients with T2DM were included in the study, with an age of 65.42±12.22 years. There were 83 males (72.2%). Fifty-four patients (47.0%) used MET, and 61 (53.0%) used other hypoglycemic drugs; 43 (37.4%) developed ENI, and 33 (28.7%) had poor outcome at 90 days. There were no significant difference in all baseline data between the MET group and the non-MET group, but the proportions of patients with ENI and good prognosis at 90 days in the MET group were significantly higher than those in the non-MET group (all P<0.05). The proportions of hypertensive patients and baseline NIHSS scores in the ENI group were significantly lower than those in the non-ENI group, while the proportions of patients using MET, antihypertensive drugs, statins, and patients with good outcome was significantly higher than that in the non-ENI group (all P<0.05). The body weight, high-density lipoprotein cholesterol, as well as the proportions of patients using antiplatelet drugs, MET, and patients with ENI in the good outcome group were significantly higher than those in the poor outcome group, while systolic blood pressure, fasting blood glucose, triglycerides, and the proportions of patients with hemorrhagic transformation, and symptomatic intracranial hemorrhage were significantly lower than those in the poor outcome group (all P<0.05). Multivariate logistic regression analysis showed that using statins (odds ratio [ OR] 5.291, 95% confidence interval [ CI] 1.599-17.514; P=0.006) and MET ( OR 3.018, 95% CI 1.125-8.092; P=0.006) were the independent influencing factors of ENI; using MET ( OR 0.014, 95% CI 0.001-0.246; P=0.004) and anterior circulation stroke ( OR 0.005, 95% CI 0.000-0.745; P=0.038) were significantly independently associated with good outcome, while high baseline NIHSS score ( OR 2.092, 95% CI 1.198-3.655; P=0.009) and serum homocysteine ( OR 1.202, 95% CI 1.024-1.411; P=0.024) were significantly independently associated with the poor outcome. Conclusion:The use of MET before stroke onset can help improve ENI and clinical outcome in AIS patients with T2DM after IVT.
